Nuvation Bio logo

Nuvation BioNYSE: NUVB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 August 2020

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$885.17 M
-59%vs. 3y high
73%vs. sector
-vs. 3y high
-vs. sector
-52%vs. 3y high
56%vs. sector
409.42
-38%vs. 3y high
97%vs. sector

Price

after hours | Fri, 15 Nov 2024 23:55:28 GMT
$2.63-$0.16(-5.76%)

Dividend

No data over the past 3 years
$727.00 K-$41.21 M

Analysts recommendations

Institutional Ownership

NUVB Latest News

Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
businesswire.com14 September 2024 Sentiment: POSITIVE

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.

Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
Zacks Investment Research08 March 2024 Sentiment: POSITIVE

Does Nuvation Bio Inc. (NUVB) have what it takes to be a top stock pick for momentum investors? Let's find out.

What type of business is Nuvation Bio?

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

What sector is Nuvation Bio in?

Nuvation Bio is in the Healthcare sector

What industry is Nuvation Bio in?

Nuvation Bio is in the Biotechnology industry

What country is Nuvation Bio from?

Nuvation Bio is headquartered in United States

When did Nuvation Bio go public?

Nuvation Bio initial public offering (IPO) was on 26 August 2020

What is Nuvation Bio website?

https://www.nuvationbio.com

Is Nuvation Bio in the S&P 500?

No, Nuvation Bio is not included in the S&P 500 index

Is Nuvation Bio in the NASDAQ 100?

No, Nuvation Bio is not included in the NASDAQ 100 index

Is Nuvation Bio in the Dow Jones?

No, Nuvation Bio is not included in the Dow Jones index

When was Nuvation Bio the previous earnings report?

No data

When does Nuvation Bio earnings report?

The next expected earnings date for Nuvation Bio is 28 February 2025